Opinion|Videos|July 31, 2024
Providing Supportive Care to Patients with NSCLC
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Advertisement
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
An analysis of the BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care in transplant-ineligible NDMM.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
A patient-reported outcomes analysis from the phase 3 IRAKLIA trial showed higher satisfaction with subcutaneous isatuximab via on-body injector.
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5